“The R21/Matrix-M™ malaria vaccine represents the start of a global effort to eradicate malaria with the addition of vaccine to other measures and highlights Oxford’s commitment to addressing global health challenges in regions heavily affected by the disease.
R21 is the second malaria vaccine to be recommended by WHO for children living in endemic areas. Along with the earlier WHO recommendation of the RTS,S vaccine, there is now many-fold greater vaccine supply for Africa where the disease kills nearly half a million children annually. The rollout of both vaccines is funded by Gavi, the Vaccine Alliance.
Integrating these vaccines into national malaria control plans, along with other interventions, aims to drastically reduce childhood mortality and strengthen the fight against malaria.”
Read more on Shipment of R21 malaria vaccine to Central African Republic marks latest milestone for child survival via University of Oxford.
Family Medicine Residency Site: Abbotsford-Mission 